30000 IU Per Week Vitamin D Treatment in PCOS Patients

A Multicentre, Phase-II, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety and the Efficacy of a Weekly Administered Dose of 30,000 IU Vitamin D (Colecalciferol) in Deficient Patients Diagnosed With PCOS

This is a human, II/b phase, multicentre, randomised, double blind, placebo-controlled study to assess the safety and the efficacy of a weekly administered dose of 30,000 IU vitamin D (colecalciferol) in deficient patients diagnosed with PCOS.

Investigational products: 30.000 IU vitamin D or placebo administered once a week for 12-weeks-long period, followed by a 12-week-long open label treatment 30.000 IU vitamin D in a follow-up period.

Each participant should be checked for regular dietary Ca intake and to assure the optimal calcium level the supplementation is provided with a commercially available Citrocalcium 200 mg tablets.

Setting:

I. Baseline and screening period:

Baseline period considered as when the exogenous Vitamin D intake should not exceed the level of 1000 IU intake per day or a total 5000 NE per week dosages applied (in forms of any Vitamin D3 medication or multivitamin products) at least for 30 days prior the assessment made.

II. Double-blind treatment period:

Once a week per os applied Vitamin D or placebo treatment for 12 weeks according to randomisation of trial subjects in a 1:1 assignment. By the end of this period an interim assessment will be performed based on the analysis of primary efficacy parameters, stratification to responder and non-responder groups.

III. Open label and follow-up phase:

An open-label 30000 IU of Vitamin D treatment on weekly basis. (Vitamin D3 Pharma Patent 30000 IU tablets) for additional 12 weeks and continue with the follow-up assessments. A compassionate use of patient diary for additional 26 weeks.

Objectives:

Primary objectives: to assess the efficacy as a recovery of ovarian function based on progesterone levels and menses diary in at least 20% of trial subjects, compared to placebo treated group Secondary Objectives: assess the efficacy and safety of orally administered vitamin D treatment by the changes in 25(OH) D levels in PCOS patients.

Explore the changes in Ovarian-morphology based on the results of standard TVUS Imaging: detection of adverse drug reactions during treatment periods, by frequency and distribution compared to follow-up periods and placebo group.

Anticipated participants: 168

Study Overview

• Status: Completed
• Conditions: Polycystic Ovary Syndrome; Vitamin D Deficiency
• Intervention / Treatment: Drug: Placebo; Drug: Cholecalciferol

• Study Type: Interventional
• Enrollment (Actual): 115
• Phase: Phase 2

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary, 1083
    • Semmelweis University - Departement Medicine and Oncology
  • Budapest, Hungary, 1112
    • MediMOM Healthy Center
  • Budapest, Hungary, 1136
    • Róbert Károly Hospital
  • Debrecen, Hungary, 4032
    • Gynpraxis Nőgyógyászat
  • Kaposvár, Hungary, 7400
    • Somogy County Kaposi Mor Teaching Hospital
  • Miskolc, Hungary, 3526
    • Borsod-Abaúj-Zemplén County Hospital
  • Szeged, Hungary, 6720
    • SZTE-ÁOK - 1st Dept. of Internal MEdicine
  • Székesfehérvár, Hungary, 8600
    • Gynofarm Outpatient Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Female subject age >18 years.
• Clinical and/or biochemical hyperandrogenism and the proven PCOS by the "Rotterdam" criteria, (ovarian dysfunction, oligo- and/or anovulation, and the morphology of polycystic ovaries on ultrasound images when other etiologies are excluded)
• 25(OH)D levels are between 10-28 ng/ml by inclusion
• Subject can not be under any kind of ongoing hormone or metformin therapies and no indication that requires continuation
• Has the ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures
• Study subject has the ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures

Exclusion Criteria:

• Has been exposed to any investigational agent within 3 month of enrolment to the study
• Sever metabolic disease on endocrine disease in etiology different from PCOS
• Significant obesity (BMI> 36)
• Any other signs of lab results that may lead to other etiologies in differentiation, or menopause
• Increased serum calcium level results or symptoms of hypercalcemia in last one year
• Hypercalciuria or kidney stone appearance in last one year
• Sever kidney diseases (CKD 3 or higher)
• Chronic or serious disease, which can significantly influence the absorption, metabolism of vitamin D or Ca
• Heart failure or angina pectoris,
• More than 1000 IU vitamin D per day intake or in total >5000 IU per week within 1 month prior to trial (in any forms medication, or nutritional food supplement). The patient is not under hormonal therapy for ovulation stimulation purposes and was not involved in two months prior the study
• The patient is under hormonal therapy for the aim of ovulation stimulation or was involved in within 3 months prior the study
• Existence or suspected gravidity
• Any other finding or symptoms which are by the opinion of the Investigator may indicate a potential interference with the safety of participating trial subjects
• Has a known hypersensitivity to any of the investigational drug or vehicle components.

• Concomitant medication which is not allowed:

  • glycosides
  • metformin
  • magnesium-containing preparations (antacids)
  • cholestyramine and other ion exchange resins, orlistat
  • thiazide diuretics
  • regular use of microsomal enzyme inducers (anticonvulsants, sedatives, etc.).
  • corticosteroids (except for dermatological use)
  • products containing phosphorus
  • regular use of laxatives (such as paraffin oil)
  • fat absorption inhibitory drugs
  • any kind of hormone therapy (including therapeutic use of birth control pills, within 2 months prior inclusion) except treatment of stabile hypothyroidism

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cholecalciferol; Cholecalciferol 30,000IU weekly orally	Drug: Cholecalciferol; 30,000IU cholecalciferol
Placebo Comparator: Placebo; Placebo tablets weekly orally	Drug: Placebo; Placebo tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recovery of ovarian function	Recovery of ovarian function is detected by changes in progesterone levels (lutal phase progesterone level reaches 2 ng/ml)	Up to 32 weeks, continuously

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of menstrual cycle	Determined by patient reported number of days between two menstrual cycles	Up to 32 weeks
Variation in menstrual cycles length	Determined by patient reported menstrual cycle length and regularity, measured in days	Up to 32 weeks
Incidence of adverse events	Incidence of adverse events (safety and tolerability), evaluated at every visit	Up to 32 weeks, continuously
Change in serum calcium level	Change in serum calcium levels in mmol/l (safety measure), evaluated every clinical visit	Up to 32 weeks, continuously
Change in urinary calcium/creatinine ratio	Change in urinary calcium/creatinine ratio ([mmol/l]/[umol/l]) (safety measure), evaluated every clinical visit	Up to 32 weeks
25(OH)D levels	Evaluation of treatment of changes in 25(OH)D blood levels compared between treatment groups	Up to 32 weeks
Change in fasting glucose level	Change in fasting glucose level (mmol/l), measured at every visit	Up to 32 weeks
Change in hemoglobin A1c level	Change in hemoglobin A1c level (IFCC validated, mmol/mol), measured every 12 weeks	Up to 32 weeks
Change in ovarian morphology	Changes in ovarian follicle count assessed by TVUS and evaluated by the Rotterdam criteria (having 12 or more follicles, measuring between 2 and 9 mm)	Up to 32 weeks

Collaborators and Investigators

• Sponsor: Semmelweis University
• Collaborators: Pharma Patent Kft.
• Investigators: Principal Investigator: István Takács, MD, DSc., Semmelweis University - Dept. of Medicine and Oncology

Study record dates

Study Major Dates

• Study Start (Actual): December 8, 2016
• Primary Completion (Actual): February 1, 2022
• Study Completion (Actual): December 1, 2022

Study Registration Dates

• First Submitted: July 14, 2020
• First Submitted That Met QC Criteria: April 8, 2021
• First Posted (Actual): April 9, 2021

Study Record Updates

• Last Update Posted (Actual): June 24, 2024
• Last Update Submitted That Met QC Criteria: June 21, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Endocrine System Diseases; Ovarian Cysts; Cysts; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Nutrition Disorders; Avitaminosis; Deficiency Diseases; Malnutrition; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Polycystic Ovary Syndrome; Vitamin D Deficiency; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol
• Other Study ID Numbers: PAT15-PCODD

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No